TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. M. AU - Brummendorf, T. H. AU - Kim, D. W. AU - Turkina, A. G. AU - Shen, Z. X. PY - 2011 DA - 2011// TI - Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-05-355594 DO - 10.1182/blood-2011-05-355594 ID - Cortes2011 ER - TY - JOUR AU - Khoury, H. J. AU - Cortes, J. E. AU - Kantarjian, H. M. AU - Gambacorti-Passerini, C. AU - Baccarani, M. AU - Kim, D. W. PY - 2012 DA - 2012// TI - Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-11-390120 DO - 10.1182/blood-2011-11-390120 ID - Khoury2012 ER - TY - JOUR AU - Kantarjian, H. M. AU - Cortes, J. E. AU - Kim, D. W. AU - Khoury, H. J. AU - Brümmendorf, T. H. AU - Porkka, K. PY - 2014 DA - 2014// TI - Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-07-513937 DO - 10.1182/blood-2013-07-513937 ID - Kantarjian2014 ER - TY - JOUR AU - Cortes, J. E. AU - Kim, D. W. AU - Kantarjian, H. M. AU - Brümmendorf, T. H. AU - Dyagil, I. AU - Griskevicius, L. PY - 2012 DA - 2012// TI - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.7522 DO - 10.1200/JCO.2011.38.7522 ID - Cortes2012 ER - TY - JOUR AU - Cortes, J. E. AU - Gambacorti-Passerini, C. AU - Deininger, M. W. AU - Mauro, M. J. AU - Chuah, C. AU - Kim, D. W. PY - 2018 DA - 2018// TI - Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.74.7162 DO - 10.1200/JCO.2017.74.7162 ID - Cortes2018 ER - TY - JOUR AU - Miura, M. PY - 2015 DA - 2015// TI - Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia JO - Biol Pharm Bull VL - 38 UR - https://doi.org/10.1248/bpb.b15-00103 DO - 10.1248/bpb.b15-00103 ID - Miura2015 ER - TY - JOUR AU - Hsyu, P. H. AU - Mould, D. R. AU - Upton, R. N. AU - Amantea, M. PY - 2013 DA - 2013// TI - Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-012-1998-4 DO - 10.1007/s00280-012-1998-4 ID - Hsyu2013 ER - TY - JOUR AU - Hsyu, P. H. AU - Mould, D. R. AU - Abbas, R. AU - Amantea, M. PY - 2014 DA - 2014// TI - Population pharmacokinetic and pharmacodynamic analysis of bosutinib JO - Drug Metab Pharmacokinet VL - 29 UR - https://doi.org/10.2133/dmpk.DMPK-13-RG-126 DO - 10.2133/dmpk.DMPK-13-RG-126 ID - Hsyu2014 ER - TY - JOUR AU - Nakaseko, C. AU - Takahashi, N. AU - Ishizawa, K. AU - Kobayashi, Y. AU - Ohashi, K. AU - Nakagawa, Y. PY - 2015 DA - 2015// TI - A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia JO - Int J Hematol VL - 101 UR - https://doi.org/10.1007/s12185-014-1722-8 DO - 10.1007/s12185-014-1722-8 ID - Nakaseko2015 ER - TY - JOUR AU - Takahashi, N. AU - Nakaseko, C. AU - Kobayashi, Y. AU - Miyamura, K. AU - Ono, C. AU - Koide, Y. PY - 2017 DA - 2017// TI - Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment JO - Int J Hematol VL - 106 UR - https://doi.org/10.1007/s12185-017-2239-8 DO - 10.1007/s12185-017-2239-8 ID - Takahashi2017 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Brummendorf, T. H. AU - Kim, D. W. AU - Turkina, A. G. AU - Masszi, T. AU - Assouline, S. PY - 2014 DA - 2014// TI - Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23728 DO - 10.1002/ajh.23728 ID - Gambacorti-Passerini2014 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Cortes, J. E. AU - Lipton, J. H. AU - Dmoszynska, A. AU - Wong, R. S. AU - Rossiev, V. PY - 2014 DA - 2014// TI - Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia JO - Am J Hematol VL - 89 UR - https://doi.org/10.1002/ajh.23788 DO - 10.1002/ajh.23788 ID - Gambacorti-Passerini2014 ER - TY - JOUR AU - Garrett, M. AU - Knight, B. AU - Cortes, J. E. AU - Deininger, M. W. PY - 2017 DA - 2017// TI - Optimizing dose of bosutinib to minimize adverse events while maintaining efficacy in patients with newly diagnosed chronic myelogenous leukemia JO - Blood (ASH Annual Meeting Abstracts) VL - 130 ID - Garrett2017 ER - TY - JOUR AU - Marin, D. AU - Bazeos, A. AU - Mahon, F. X. AU - Eliasson, L. AU - Milojkovic, D. AU - Bua, M. PY - 2010 DA - 2010// TI - Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.3087 DO - 10.1200/JCO.2009.26.3087 ID - Marin2010 ER - TY - JOUR AU - Abbas, R. AU - Hug, B. A. AU - Leister, C. AU - Gaaloul, M. E. AU - Chalon, S. AU - Sonnichsen, D. PY - 2012 DA - 2012// TI - A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects JO - Cancer Chemother Pharmacol VL - 69 UR - https://doi.org/10.1007/s00280-011-1688-7 DO - 10.1007/s00280-011-1688-7 ID - Abbas2012 ER - TY - JOUR AU - Miura, M. AU - Takahashi, M. PY - 2016 DA - 2016// TI - Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC–MS/MS methods JO - Drug Metab Pharmacokinet VL - 31 UR - https://doi.org/10.1016/j.dmpk.2015.09.002 DO - 10.1016/j.dmpk.2015.09.002 ID - Miura2016 ER - TY - JOUR AU - Abumiya, M. AU - Miura, M. AU - Takahashi, N. PY - 2017 DA - 2017// TI - Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients JO - Leuk Res VL - 64 UR - https://doi.org/10.1016/j.leukres.2017.11.012 DO - 10.1016/j.leukres.2017.11.012 ID - Abumiya2017 ER -